VERMOX CHEWABLE (mebendazole) chewable tablets, 500 mg – Full Prescribing Information (NDA 208398/S-001) (2021)

Government Record · Janssen Pharmaceuticals, Inc. (labeler); U.S. Food and Drug Administration · September 2021

Janssen Pharmaceuticals et al., 2021-09: Prescribing information for the 500 mg Vermox Chewable tablet (single-dose regimen for roundworm and whipworm, patients one year and older). Its pregnancy section carries the rat teratogenicity findings and the statement that published human data show no clear association with major birth defects.

In animal reproduction studies, adverse developmental effects (i.e., skeletal malformations, soft tissue malformations, decreased pup weight, embryolethality) were observed when mebendazole was administered to pregnant rats during the period of organogenesis at single oral doses as low as 10 mg/kg

4

Janssen Pharmaceuticals et al., 2021-09: Prescribing information for the 500 mg Vermox Chewable tablet (single-dose regimen for roundworm and whipworm, patients one year and older). Its pregnancy section carries the rat teratogenicity findings and the statement that published human data show no clear association with major birth defects. Revised 9/2021; Reference ID 4859761. Dose: one 500 mg tablet as a single dose, chewed, for Ascaris and Trichuris, age 1 year and older; 'can be taken without regard to food intake'. Safety pool 677 children aged 1-16 and 34 adults at the single 500 mg dose. NDA 208398 was a Type 5 new-formulation application approved 2016-10-19 (Drugs@FDA), marketing status now 'Discontinued'. PDF checked page 4 of 11 by pdftotext. Context: NDA 208398, approved 2016, now discontinued in the U.S. (openFDA). Also filed as MBA-04, MBA-08 (claims C1, C3).